Rule of Prevention: a potential framework to evaluate preventive interventions for rare diseases
ABSTRACTBackground: The benefits of preventive interventions lack comprehensive evaluation in standard health technology assessments (HTA), particularly for rare and transmissible diseases.Objective: To identify possible considerations for future HTA using analogies between the treatment and prevent...
Saved in:
| Main Authors: | Eddie Gibson, Daniel A. Ollendorf, Steven Simoens, David E Bloom, Federico Martinón-Torres, David Salisbury, Johan Louis Severens, Mondher Toumi, Daniel Molnar, Kinga Meszaros, Woo-Yun Sohn, Najida Begum |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-12-01
|
| Series: | Journal of Market Access & Health Policy |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20016689.2023.2239557 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Quantifying the persisting orphan-drug shortage public health crisis in the United States
by: Szymon Jarosławski, et al.
Published: (2017-01-01) -
A comparative study of orphan drug prices in Europe
by: Katherine Eve Young, et al.
Published: (2017-01-01) -
Patient-reported outcome claims in European and United States orphan drug approvals
by: Szymon Jarosławski, et al.
Published: (2018-01-01) -
Low rates of patient-reported outcome claims for orphan drugs approved by the us food and drug administration
by: Szymon Jarosławski, et al.
Published: (2018-01-01) -
Do payers value rarity? An analysis of the relationship between disease rarity and orphan drug prices in Europe
by: Goran Medic, et al.
Published: (2017-01-01)